-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Today, Turnstone Biologics announced that it has reached a multi-year strategic research cooperation with Moffitt Cancer Center to jointly conduct research on tumor infiltrating lymphocyte (TIL) therapy
TIL is a lymphocyte that migrates into the tumor when cancer occurs and attacks the tumor
Turnstone’s unique technology platform will discover tumor-related T cells in TIL, combined with advanced cell screening and culture technology, to quickly enrich T cells that eliminate tumors and preserve the diversity of T cell targeted antigens.
▲Turnstone's TIL technology platform (picture source: Turnstone official website)
According to the agreement, Moffitt will collaborate to discover, enrich and expand TILs that recognize neoantigens in a variety of solid tumors, including melanoma, breast cancer, and rectal cancer
Reference materials:
[1] Turnstone Biologics Announces Research Collaboration with Moffitt Cancer Center to Advance Novel TIL Immunotherapies for Solid Tumor Indications.
(The original text has been deleted)